Sandoz, a Swiss pharmaceutical company, has opened a $99 million biosimilar development center in Ljubljana, Slovenia. This new facility marks the first phase of a larger, three-part investment strategy aimed at establishing a comprehensive, in-house biosimilar development and manufacturing center within Europe. The Ljubljana center will focus on the complete development process for biosimilars, utilizing fully digital technologies. Sandoz intends for Slovenia to become a key location for its biosimilar operations, strengthening its position in the rapidly growing biosimilars market. The company anticipates this investment will enhance its capabilities to deliver more affordable biologic medicines to patients. This project represents a significant economic contribution to Slovenia and reinforces the country’s growing role in the pharmaceutical industry. Further investments are planned as part of this broader European hub initiative.